The CDC’s Advisory Committee on Immunization Practices (ACIP) recently voted in favor of a Category B recommendation for meningococcal group B vaccination in adolescents and young adults aged 16 to 23 years.
The Category B recommendation states that vaccine decisions should be made by healthcare professionals based on individual patient risk. The ACIP also voted to include meningococcal group B vaccines in the CDC’s Vaccines for Children program for adolescents aged 16 to 18 years.
In February 2015 the Committee voted to recommend serogroup B meningococcal vaccination for individuals aged 10 years and older who are at increased risk for meningococcal disease.
The ACIP recommendations will be sent to the director of the CDC and the U.S. Department of Health and Human Services for review and approval. Currently, there are two serogroup B meningococcal vaccines — Bexsero (GlaxoSmithKline) and Trumenba (Pfizer) — that are approved by the FDA for meningococcal group B vaccination in individuals aged 10 to 25 years.
This article originally appeared on MPR